| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6441168 | BAYER HLTHCARE | Stable crystalline salts of 5-methyltetrahydrofolic acid |
Jul, 2022
(1 year, 1 month ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7163931 | BAYER HLTHCARE | Compositions of estrogen-cyclodextrin complexes |
Mar, 2022
(1 year, 6 months ago) | |
| US8617597 | BAYER HLTHCARE | Pharmaceutical composition containing a tetrahydrofolic acid |
Feb, 2030
(6 years from now) | |
| US11617751 | BAYER HLTHCARE | Pharmaceutical composition containing a tetrahydrofolic acid |
Jul, 2030
(6 years from now) | |
Beyaz is owned by Bayer Hlthcare.
Beyaz contains Drospirenone; Ethinyl Estradiol; Levomefolate Calcium.
Beyaz has a total of 4 drug patents out of which 2 drug patents have expired.
Expired drug patents of Beyaz are:
- US7163931
- US6441168
Beyaz was authorised for market use on 24 September, 2010.
Beyaz is available in tablet;oral dosage forms.
Beyaz can be used as prevention of pregnancy; raise folate levels in women who choose to use an oral contraceptive as their method of contraception for the purpose of reducing the risk of a neural tube defect in a pregnancy; treatment of moderate acne vulgaris in women at least 14 years of age if the patient desires an oral contraceptive for birth control; treatment of mood changes and/or anxiety as symptoms of premenstrual dysphoric disorder (pmdd) in women who choose to use an oral contraceptive as their method of contraception, prevention of pregnancy.
The generics of Beyaz are possible to be released after 17 July, 2030.
Drugs and Companies using DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM ingredient
Market Authorisation Date: 24 September, 2010
Treatment: Prevention of pregnancy; Raise folate levels in women who choose to use an oral contraceptive as their method of contraception for the purpose of reducing the risk of a neural tube defect in a pregnan...
Dosage: TABLET;ORAL
BEYAZ family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic